Al's Comment:

 They reported median survival of 20  months for recurrent glioblastoma.  84% alive 1 year after starting treatment.   This is unheard of and is a breakthrough in brain tumor treatments.  It was a single arm trial so no randomized controls, but we would expect 8-9 months.    It is approved in Japan, but we can not get it in the USA. I tried asking the company to open a trial or expanded access here and they do not want to yet, because of our regulatory system.  We need to change this now.   


Posted on: 08/21/2022

Intratumoral oncolytic herpes virus G47delta for residual or recurrent glioblastoma: a phase 2 trial

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!